Literature DB >> 27149341

Still room for improvement: Preclinical and bench testing of a thin-strut cobalt-chromium bare-metal stent with passive coating.

Eric Wittchow1, Sonja Hartwig2.   

Abstract

There is a renewed interest in bare-metal stent (BMS) design as degradable polymer coatings are increasingly used as drug-delivery vehicles in drug-eluting stents (DESs), leaving it to the BMS platform to determine the long-term outcome of DES treatment. In this study comprising preclinical and bench tests, we compare two modern thin-strut BMSs of different design. Angiography, morphometry, and histopathology data were acquired in a porcine coronary artery model in a 28-day single-stent study (13 hybrid farm pigs) and in a 90-day overlapping-stent study (8 Yucatan mini-pigs). Standardized bench tests including ion release test were performed to compare mechanical performance of the two stent systems. We found that the optimized stent group induced significantly less neointimal formation and less inflammation than Multi-Link Vision in both (single stent and overlapping stent) porcine studies. The higher efficacy was also associated with a markedly reduced release of cobalt, nickel, chromium, and tungsten ions in physiological solution and better performance in mechanical delivery tests. In conclusion, a further increase in efficacy and better safety profile than the well-known Multi-Link Vision BMS can be achieved by careful optimization of the BMS backbone.
© 2016 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 105B: 1612-1621, 2017. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  deliverability; drug-eluting stent platform; heavy metal ion release; preclinical study; stent design

Mesh:

Substances:

Year:  2016        PMID: 27149341     DOI: 10.1002/jbm.b.33702

Source DB:  PubMed          Journal:  J Biomed Mater Res B Appl Biomater        ISSN: 1552-4973            Impact factor:   3.368


  1 in total

1.  Do ultrathin strut bare-metal stents with passive coating improve efficacy in large coronary arteries? Insights from the randomized, multicenter BASKET-PROVE trials.

Authors:  Kim Wadt Hansen; Raban Jeger; Rikke Sørensen; Christoph Kaiser; Matthias Pfisterer; Tor Biering-Sørensen; Louise Hougesen Bjerking; Søren Galatius
Journal:  BMC Cardiovasc Disord       Date:  2019-10-16       Impact factor: 2.298

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.